ArticleBMC chemistry2025
Total synthesis and biological evaluation of Koshidacin B, TAN-1746, and Ac-TAN-1746.
Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Analogues of chlamydocin derivatives consistently demonstrate multifaceted bioactivities, particularly through HDAC inhibition mechanisms, oncolytic efficacy, and neuronal preservation capacities. These activities primarily originate from their unique cyclic tetrapeptide scaffold and functional groups within the side chains that enable specific interactions with biomacromolecules. We herein report the total syntheses of three naturally occurring chlamydocin analogues-koshidacin B, TAN-1746, and Ac-TAN-1746. The synthetic strategy employed a modular approach that involved modifying a common intermediate via late-stage olefin cross-metathesis to install the requisite side-chain fragments. This versatile approach enabled an efficient and divergent total synthesis of the target compounds, completing the syntheses in a longest linear sequence of 9-10 steps. Remarkably, TAN-1746 and Ac-TAN-1746 demonstrated significant anti-osteosarcoma activity that exceeded the potency of clinically employed cisplatin-an observation not previously documented. These results strongly validate the utility of the chlamydocin scaffold as a platform for the development of potent inhibitors with promising therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.